2 July 2015

Company Announcements Office
Australian Securities Exchange
10th Floor
20 Bond Street
SYDNEY NSW 2000

Dear Sir

COMPLETION OF ACQUISITION OF RESAPP DIAGNOSTICS PTY LTD

The Company is pleased to announce that the Share Sale Agreement dated 20 February 2015 between the Company, ResApp Diagnostics Pty Ltd ("**ResApp**"), the Shareholders of ResApp and UniQuest Pty Ltd has completed with the Company acquiring 100% of ResApp.

In accordance with the Company's Replacement Prospectus dated 26 May 2015 and as approved by Shareholders at the General Meeting held on 27 May 2015, the following securities have been issued:

(a) Vendor Offer – 93,750,000 Shares and 93,750,000 Performance Shares issued in consideration for the acquisition of ResApp;
(b) Public Offer – 200,000,000 Shares at $0.02 per Share having raised $4 million;
(c) Facilitation Offer – 18,749,999 Shares to the Facilitators for services provided; and
(d) Incentive Options – 20 million Incentive Options.

Following completion of the acquisition, Dr Tony Keating has been appointed to the Board of the Company in the position of Managing Director and Chief Executive Officer. Dr Roger Aston has also been appointed as a non-executive director, replacing Dr Rob Ramsay.

In addition, the Company has changed its name from Narhex Life Sciences Limited to ResApp Health Limited and will be reinstated under the new ASX Code "RAP".

The Company is currently finalising all outstanding ASX conditions for reinstatement and will update the market once a reinstatement date has been confirmed.

Yours faithfully

Nicki Farley
Company Secretary

ResApp Health Limited
ABN 51 094 468 318
Level 24, 44 St Georges Terrace, Perth WA 6000
Tel: 08 6211 5099 Fax: 08 9218 8875